Protagonist Therapeutics (PTGX) Earnings Date, Estimates & Call Transcripts $46.61 +1.04 (+2.28%) Closing price 05/20/2025 04:00 PM EasternExtended Trading$46.87 +0.26 (+0.56%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Protagonist Therapeutics Earnings Summary Protagonist Therapeutics announced Q1 2025 earnings on May 6, 2025, reporting an EPS of -$0.19, which beat the consensus estimate of -$0.50 by $0.31. Quarterly revenue was reported to be $28.32 million, below analysts' expectations of $30.44 million. With a trailing EPS of $0.75 and a P/E Ratio of 17.52, Protagonist Therapeutics' earnings are expected to decrease next year, from $2.43 to ($0.64) per share. Upcoming Q2 Earnings DateAug. 5Before Market OpensEstimatedConsensus EPS (May. 6) -$0.50 Actual EPS (May. 6) -$0.19 Beat By $0.31 Actual Revenue (May. 6) $28.32MQ1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)PTGX Upcoming EarningsProtagonist Therapeutics' next earnings date is estimated for Tuesday, August 5, 2025, based on past reporting schedules. Powered by Get Protagonist Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataPTGX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.PTGX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Protagonist Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.57$1.92$0.68Q2 20252-$0.67-$0.59-$0.63Q3 20252-$0.65-$0.48-$0.57Q4 20252-$0.64$0.93$0.15 FY 2025 8 -$2.53 $1.78 -$0.38 Q1 20261$0.03$0.03$0.03Q2 20261-$0.72-$0.72-$0.72Q3 20261-$0.75-$0.75-$0.75Q4 20261$0.03$0.03$0.03 Protagonist Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/5/2025(Estimated)--------5/6/2025Q1 2025-$0.50-$0.19+$0.31-$0.19$30.44M$28.32M2/21/2025Q4 2024-$0.09$1.98+$2.07$1.98$56.65M$170.64M11/7/2024--$0.59-$0.54+$0.05-$0.54$4.50M$4.68M8/6/2024--$0.50-$0.50--$0.50$40.00M$4.17M5/7/2024Q1 2024$2.51$3.26+$0.75$3.26$300.00M$254.95M2/27/2024Q4 2023$0.05$0.44+$0.39$0.44$60.00M$60.00M11/2/2023Q3 2023-$0.68-$0.58+$0.10-$0.58--8/3/2023Q2 2023-$0.65-$0.68 -$0.03-$0.68-- Protagonist Therapeutics Earnings - Frequently Asked Questions When is Protagonist Therapeutics's earnings date? Protagonist Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 5th, 2025 based off last year's report dates. Learn more on PTGX's earnings history. Did Protagonist Therapeutics beat their earnings estimates last quarter? In the previous quarter, Protagonist Therapeutics (NASDAQ:PTGX) reported ($0.19) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.50) by $0.31. Learn more on analysts' earnings estimate vs. PTGX's actual earnings. How much revenue does Protagonist Therapeutics generate each year? Protagonist Therapeutics (NASDAQ:PTGX) has a recorded annual revenue of $207.80 million. How much profit does Protagonist Therapeutics generate each year? Protagonist Therapeutics (NASDAQ:PTGX) has a recorded net income of -$78.96 million. PTGX has generated $0.75 earnings per share over the last four quarters. What is Protagonist Therapeutics's price-to-earnings ratio? Protagonist Therapeutics (NASDAQ:PTGX) has a trailing price-to-earnings ratio of 17.52 and a forward price-to-earnings ratio of 19.18. What is Protagonist Therapeutics's EPS forecast for next year? Protagonist Therapeutics's earnings are expected to decrease from $2.43 per share to ($0.64) per share in the next year. More Earnings Resources from MarketBeat Related Companies Viatris Earnings Date Moderna Earnings Date Qiagen Earnings Date Ascendis Pharma A/S Earnings Date Roivant Sciences Earnings Date Revolution Medicines Earnings Date BridgeBio Pharma Earnings Date Blueprint Medicines Earnings Date Elanco Animal Health Earnings Date Legend Biotech Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds This page (NASDAQ:PTGX) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTGX Stock Free PTGX Stock Alerts